Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:25:44 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Q:VERU - VERU INC - http://verupharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VERU - Q0.11.19·1.360.21.32-0.05-3.61,584.41,9263,5351.39  1.39  1.251.92  0.3619:46:51May 1515 min RT 2¢

Recent Trades - Last 10 of 3535
Time ETExPriceChangeVolume
19:46:51Q1.35-0.0212
19:46:51Q1.35-0.02600
19:33:51Q1.33-0.041,000
19:18:51Q1.3298-0.0402500
18:42:25Q1.33-0.04200
18:19:07Q1.33-0.042,535
17:42:00Q1.32-0.05540
17:41:52Q1.32-0.053,700
17:29:30Q1.3199-0.05011
17:28:07Q1.31-0.061,500

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-15 08:30U:VERUNews ReleaseVeru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
2024-05-14 08:30U:VERUNews ReleaseVeru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
2024-05-08 06:30U:VERUNews ReleaseVeru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
2024-05-02 08:30U:VERUNews ReleaseVeru to Present at the GLP-1 Based Therapeutics Summit
2024-05-01 08:31U:VERUNews ReleaseVeru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
2024-04-30 08:30U:VERUNews ReleaseVeru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
2024-04-25 08:30U:VERUNews ReleaseVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
2024-04-01 16:05U:VERUNews ReleaseVeru Announces Date of 2024 Annual Meeting of Shareholders
2024-03-22 16:05U:VERUNews ReleaseVeru Reschedules Annual Meeting of Shareholders
2024-03-12 08:00U:VERUNews ReleaseVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
2024-02-27 19:15U:VERUNews ReleaseVeru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
2024-02-20 08:30U:VERUNews ReleaseVeru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
2024-02-08 06:30U:VERUNews ReleaseVeru Reports Fiscal 2024 First Quarter Financial Highlights
2024-02-06 08:30U:VERUNews ReleaseVeru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
2024-01-31 08:30U:VERUNews ReleaseVeru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-01-25 08:30U:VERUNews ReleaseVeru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
2024-01-08 08:30U:VERUNews ReleaseVeru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
2023-12-19 08:30U:VERUNews ReleaseVeru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
2023-12-14 09:00U:VERUNews ReleaseVeru Announces Pricing of Public Offering of Common Stock
2023-12-13 16:01U:VERUNews ReleaseVeru Announces Proposed Public Offering of Common Stock